The purpose of this study is to examine the effect of a low-dose ketamine infusion on depression symptoms within the Emergency Department (ED) visit, and healthcare utilization after leaving the ED, when administered in the ED for depression or suicidal ideation.
Topic Depression
Suicidality
Country United States of America
Visit trial
Status
Planned
Results Published
No
Start date
18 October 2019
End date
31 May 2020
Chance of happening
100%
Phase
Phase IV
Design
Blinded
Type
Interventional
Generation
First
Participants
29
Sex
All
Age
18- 99
Therapy
No
Trial Details
Patients will be identified based on either a chief complaint of suicidal ideation, suicide attempt, or severe depression, or if the patient indicates during intake assessment that they have thoughts of harming or killing their self. Identified patients will be assessed by the ED provider for inclusion and exclusion criteria. If the patient is a candidate for the trial and gives their informed consent for enrollment, they will be randomized to receive either ketamine or placebo by a computer program that maintains blinding. The patient will be assessed by psychiatry for disposition and treatment plan prior to receiving the study drug, and will be reassessed four hours after the infusion. Thirty days after the patient leaves the hospital (either leaves from the ED or is discharged from inpatient admission), they will be contacted to follow up on their healthcare utilization after discharge.NCT Number NCT04266288
Sponsors & Collaborators
MercyOne Des Moines Medical CenterThis company doesn't have a full profile yet, it is linked to a clinical trial.